Postoperative Pain After Cesarean SectionNCT07478692
Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery
A study testing The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg) in people with Postoperative Pain After Cesarean Section, run by Qing Yuan at 2 sites in China.
Trial summary
ltrasound-guided transversus abdominis plane (TAP) block is an emerging local anesthesia technique that effectively alleviates postoperative pain by injecting anesthetic drugs around the nerves in the abdominal wall. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Postoperative Pain After Cesarean Section
- What is being tested?
- The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 83 participants
- Where
- 2 sitesChina
- Study dates
- 1 Jun 2025to 31 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Aged 20-40 years, in good general health
- ASA physical status I-II
- Singleton, term (37-41 weeks) pregnancy with normal fetal development
- Planned for elective cesarean section, no labor
Who cannot join
- Pregnancy complications (e.g., severe preeclampsia, gestational diabetes, placental abruption)
- Major organ dysfunction (heart, liver, kidney) or psychiatric history
- Allergy to local anesthetics or any study drugs
- Prior abdominal surgery or infection that may affect block efficacy
- Coagulation disorders or current anticoagulant use
- Refusal to participate or inability to comply with follow-up
Trial locations and contacts
2 sites in 1 country.
China2 sites
Shandong Provincial Maternal and Child Health Care Hospital
Jinan, Shandong, 250014
Shandong Provincial Maternal and Child Health Care Hospital
Jinan, Shandong
About this study
ltrasound-guided transversus abdominis plane (TAP) block is an emerging local anesthesia technique that effectively alleviates postoperative pain by injecting anesthetic drugs around the nerves in the abdominal wall. Compared with traditional analgesic methods, TAP blockade may have better analgesic effects and fewer side effects. However, current research on the application of TAP blockade after cesarean section is still limited. Therefore, this study will systematically evaluate its actual effectiveness in pain management after cesarean section through a prospective randomized controlled trial
- Being tested
- The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)Drug
the control group received only the same formula intravenous analgesia pump
| Study group | Role | What they receive |
|---|---|---|
| TAP Block Group | Experimental | The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg + tropisetron 8 mg); Receives: Drug: The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg) |
| the control group | No intervention | received only the same formula intravenous analgesia pump. For both groups, rescue |
What is being measured
The primary outcome is the main question the study is designed to answer.
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity ( Time to first rescue analgesia requirement and number of patients and total dosage of flurbiprofen axetil used within 48 hours postoperatively;
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity (coughing or turning) at 2, 6, 12, 24, and 48 hours postoperatively were recorded by anesthesiologists not involved in this study.
Measured: 5 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Jun 2025
- Primary completion31 Oct 2025
- Study completion31 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative Pain After Cesarean SectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 83 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qing Yuan
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Qing Yuan, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07478692
- Sponsor's protocol ID
- 202318001040
- Status last verified
- Mar 2026
- First submitted
- 7 Mar 2026
- Last updated
- 17 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Transversus Abdominis Plane Block on Recovery Quality and Maternal-Neonatal Outcomes After Cesarean Delivery
- ClinicalTrials.gov ID
- NCT07478692
- Acronym / sponsor ID
- 202318001040
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 83 participants (actual)
- Lead sponsor
- Qing YuanUniversity, hospital or other
- Study start
- 1 Jun 2025 (actual)
- Primary completion
- 31 Oct 2025 (actual)
- Study completion
- 31 Oct 2025 (actual)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ltrasound-guided transversus abdominis plane (TAP) block is an emerging local anesthesia technique that effectively alleviates postoperative pain by injecting anesthetic drugs around the nerves in the abdominal wall. Compared with traditional analgesic methods, TAP blockade may have better analgesic effects and fewer side effects. However, current research on the application of TAP blockade after cesarean section is still limited. Therefore, this study will systematically evaluate its actual effectiveness in pain management after cesarean section through a prospective randomized controlled trial
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| TAP Block Group | Experimental | Drug: The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg + tropisetron 8 mg); |
| the control group | No intervention | –received only the same formula intravenous analgesia pump. For both groups, rescue |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Aged 20-40 years, in good general health
- ASA physical status I-II
- Singleton, term (37-41 weeks) pregnancy with normal fetal development
- Planned for elective cesarean section, no labor
Key exclusion criteria (6 listed)
- Pregnancy complications (e.g., severe preeclampsia, gestational diabetes, placental abruption)
- Major organ dysfunction (heart, liver, kidney) or psychiatric history
- Allergy to local anesthetics or any study drugs
- Prior abdominal surgery or infection that may affect block efficacy
- Coagulation disorders or current anticoagulant use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg)the control group received only the same formula intravenous analgesia pump | Drug | TAP Block Group |
Primary outcome
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity ( Time to first rescue analgesia requirement and number of patients and total dosage of flurbiprofen axetil used within 48 hours postoperatively;
Time frame: 5 months
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity (coughing or turning) at 2, 6, 12, 24, and 48 hours postoperatively were recorded by anesthesiologists not involved in this study.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain After Cesarean Section
Not yet recruiting
Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean Section
Cesarean Section (MeSH: D002585), Postoperative Pain After Cesarean Section
Recruiting
Lateral QL Block vs Intrathecal Morphine for Cesarean Section
Anesthesia, Postoperative Pain
Not yet recruiting
Effect of Sacral Erector Spinae Plane Block on Quality of Recovery After Cesarean Delivery: A Prospective Randomized Controlled Trial
Pain, Postoperative Pain
Recruiting
Reducing Chronic Pain Following Cesarean Delivery
Chronic Pain, Cesarean Section Complications
Recruiting
Impact of the NeuroCuple Device on Pain Management After Cesarean Delivery
Pain, Analgesia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing The TAP block group received ultrasound-guided bilateral TAP block (20 mL of 0.375 % ropivacaine per side) during surgery and postoperative intravenous analgesia pump (formula of butorphanol 2 mg/kg) in people with Postoperative Pain After Cesarean Section, run by Qing Yuan at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
VAS pain scores (0-10 scale, where 0 = no pain and 10 = unbearable severe pain) at rest and during activity ( Time to first rescue analgesia requirement and number of patients and total dosage of flurbiprofen axetil used within 48 hours postoperatively; (time frame: 5 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2026.